{"filing":{"accession_number":"0001193125-26-346859","cik":"0001781174","ticker":"ACRV","company_name":"Acrivon Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"acrv-20260812.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1781174/000119312526346859/acrv-20260812.htm"},"events":[{"id":27199,"run_id":24772,"accession_number":"0001193125-26-346859","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Acrivon issued a press release on August 12, 2026 announcing financial results for the quarter ended June 30, 2026, including net loss of $17.964 million, R\u0026D expenses of $13.844 million, and cash position of $90.0 million as of June 30, 2026. The filing includes condensed consolidated statements of operations and balance sheets, which are typical of a quarterly earnings disclosure. This is a standard Item 2.02 earnings release for a clinical-stage biotech company.","company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28622,"accession_number":"0001193125-26-346859","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Acrivon issued a press release on August 12, 2026 announcing financial results for the quarter ended June 30, 2026, including net loss of $17.964 million, R\u0026D expenses of $13.844 million, and cash position of $90.0 million as of June 30, 2026. The filing includes condensed consolidated statements of operations and balance sheets, which are typical of a quarterly earnings disclosure. This is a standard Item 2.02 earnings release for a clinical-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:15:14.008423+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28622,"accession_number":"0001193125-26-346859","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Acrivon issued a press release on August 12, 2026 announcing financial results for the quarter ended June 30, 2026, including net loss of $17.964 million, R\u0026D expenses of $13.844 million, and cash position of $90.0 million as of June 30, 2026. The filing includes condensed consolidated statements of operations and balance sheets, which are typical of a quarterly earnings disclosure. This is a standard Item 2.02 earnings release for a clinical-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:15:14.008423+00:00","company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","filing_date":"2026-08-12"}]}